Brief: Kelun-Biotech's Sac-TMT + Pembrolizumab Improves Survival In Late-Stage China Trial
21/05/2026 22:03
May 22 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL-SAFETY PROFILE OF SAC-TMT + PEMBROLIZUMAB GENERALLY MANAGEABLE, CONSISTENT WITH SAFETY PROFILE OF COMPONENTS SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL: SACITUZUMAB TIRUMOTECAN + PEMBROLIZUMAB EXTENDED PFS VERSUS PEMBROLIZUMAB ALONE IN PHASE 3 LUNG CANCER TRIAL SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL: OBJECTIVE RESPONSE RATE 70.2% WITH SAC-TMT PLUS PEMBROLIZUMAB VERSUS 42.0% WITH PEMBROLIZUMAB ALONE Further company coverage: 6990.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials